Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Silence Therapeutics plc (SLN)

Silence Therapeutics to be acquired by Merck KGaA for $20.00 per ADS in cash

Positive Impact 5 of 5 m&a Written later

Silence Therapeutics agreed on October 18, 2026 to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash deal valued at about $1.3 billion in equity value. Shareholders and ADS holders would receive $20.00 in cash per American Depositary Share, a 130% premium to the October 16, 2026 closing ADS price, and the transaction was unanimously approved by the Silence board.

Key points

  • Consideration of $20.00 in cash per ADS, with each ADS representing three ordinary shares ($6.6667 per share)
  • Equity value of approximately $1.3 billion and enterprise value of $1.1 billion; 82% premium to the 30-day volume-weighted average price of $10.99
  • Expected close in the first quarter of 2027, subject to shareholder approval, High Court sanction and regulatory approvals; End Date of April 30, 2027
  • Silence must pay Merck KGaA a $13 million termination fee in certain circumstances; securityholders with about 14% of voting power signed voting and support agreements

The filing

CompanySilence Therapeutics plc (SLN)
Form8-K, current report
Filed with the SECOct 19, 2026, 8:05 AM ET
Accession number0001193125-26-424695

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.